1. Pink Sheet
  2. >>Market Access

Part D Copay Smoothing: Manufacturers Excluded From Financial Reconciliation Process

 
• By Cathy Kelly

Aiming for a threshold that ‘strikes the best balance,’ the final guidance from Medicare requires that plan sponsors and pharmacies use $600, single-prescription cost sharing at the point of sale to identify enrollees likely to benefit from the smoothing program and inform them about the option.

Part D Cost Sharing Can Be Spread Out Over The Year Beginning In 2025 • Source: Shutterstock (Shutterstock)

Manufacturers may not engage in the financial reconciliation process between Medicare Part D plans and beneficiaries as part of the cost sharing “smoothing” program established by the Inflation Reduction Act, according to final guidance by the Centers for Medicare and Medicaid Services.

Key Takeaways

  • Manufacturers can’t insert themselves in the reconciliation process between plans and beneficiaries, final guidance says.

  • Beneficiaries with $600 single script cost sharing bill will...

The smoothing program is intended to make it easier for beneficiaries with very high-cost prescriptions to afford their co-pays by permitting monthly installments rather than demanding collection of the whole...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Market Access

GLP-1 Pricing ‘Paradigm Shift’ Possible, But Would It Meet Trump’s MFN Goals?

 
• By Cathy Kelly

For the Trump Administration, the blockbuster GLP-1 drugs for obesity have become a poster child for the disparity between US and foreign prices.

Japan Price Cuts For Epkinly and Lunsumio Following CEA

 
• By Lisa Takagi

Japan is cutting more drug reimbursement prices following cost effectiveness analysis and is applying the methodology to a new group of products including Wegovy and Leqembi.

Rocky Rollout Spells Trouble for Medicare Prescription Payment Plan

 
• By Lauren Flynn Kelly

Enrollment in the new Medicare Prescription Payment Plan was lower than expected in the first year and well below CMS expectations, and invoicing data indicates members are slow to pay.

PBM Investigation, Enforcement Action ‘Critical Priorities’ At FTC, Chair Says

 
• By Cathy Kelly

The new FTC chair addressed concerns that staffing cuts will undermine the commission’s commitment to pharmacy benefit manager oversight.

More from Pink Sheet

How Pharma Companies Can Mitigate The Impact Of US Tariffs On The Supply Chain

 
• By Ewan Townsend

If US tariffs on pharmaceutical supply chain products come into force they could be disruptive for companies. Ewan Townsend, of the international law firm Arnold & Porter, explains how companies can mitigate issues through negotiating with suppliers and reallocating tariff responsibilities.

‘The Question Is, What’s Going To Happen Next?’ – The Future For Biosimilars In Europe

 
• By Dave Wallace

With European biosimilars developers buoyed by recent regulatory moves, Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil discuss the next steps forward for the industry.